[Jiuzhou Medical, the test kit seller, hits another limit-up, has invested in DeepSeek, Dark Side of the Moon, and StepStar] According to monitoring by Dongcha Beating, Jiuzhou Medical has hit the daily limit-up for the fourth consecutive trading day, achieving a 4-day streak. The company expects its net profit attributable to shareholders in the first half of the year to be between 2.8 billion and 3.4 billion yuan, a year-on-year increase of 204.29% to 269.50%. The significant profit growth is primarily driven by the valuation increase of its sci-tech investment targets. The latest unusual movement announcement revealed that Jiuzhou Hong Kong indirectly invested 750 million yuan in DeepSeek through Tianjin Shixiang. After the transaction is completed, the company will hold approximately 0.21% of the shares on a look-through basis and will not participate in operations. Jiuzhou Medical has also invested in two other domestic large-scale model companies. In August 2023 and March 2024, its subsidiary made two investments in Dark Side of the Moon, amounting to approximately $10 million and $20 million, respectively. In June 2026, the company indirectly invested 100 million yuan in StepStar through the Haitang Tonghui Fund. The shareholding ratios of these investments are relatively low and are primarily financial investments. The 2025 annual report shows that Jiuzhou Medical has committed 2.48 billion yuan to a sci-tech parent fund. After leveraging, the sub-fund pool is expected to reach nearly 13.7 billion yuan. The company also has six direct investment projects, with a total investment amount of 330 million yuan. While medical devices remain its core business, profits are increasingly influenced by the valuations of primary market projects. The company also cautions that these investments have long recovery periods, low liquidity, and carry risks of valuation declines and losses. [Original Link]